Medicaid preferred drug lists' costs to physicians

Medical Care

Volumn 46, Issue 1, 2008, Pages 9-16

  Ketcham, Jonathan D ^a   Epstein, Andrew J ^b  

^a ARIZONA STATE UNIVERSITY   (United States)

^b YALE UNIVERSITY   (United States)

Author keywords

Administrative costs; Medicaid formularies; Medicare part D; Physician prescribing patterns; Prescription drug coverage

Indexed keywords

ANTIHYPERTENSIVE AGENT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

ARTICLE; CARDIOLOGY; CLINICAL PRACTICE; ECONOMICS; GENERAL PRACTITIONER; HUMAN; MEDICAID; ORGANIZATION AND MANAGEMENT; PHYSICIAN; PRESCRIPTION; PRIMARY HEALTH CARE; PUBLICATION; UNITED STATES;

ANTIHYPERTENSIVE AGENTS; CARDIOLOGY; FORMULARIES; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MEDICAID; PHYSICIAN'S PRACTICE PATTERNS; PHYSICIANS; PHYSICIANS, FAMILY; PRESCRIPTIONS, DRUG; PRIMARY HEALTH CARE; UNITED STATES;

EID: 37649025669     PISSN: 00257079     EISSN: None     Source Type: Journal    
DOI: 10.1097/MLR.0b013e31814b8245     Document Type: Article

References (41)

1. National Health Expenditures Data, Centers for Medicare and Medicaid Services, Office of the Actuary, National Health Statistics Group [Centers for Medicare and Medicaid Services web site]. April 26, 2006. Available at: http://www.cms.hhs.gov/NationalHealthExpendData. Accessed May 30, 2007.
2. Crowley J, Ashner D, Elam L. State Medicaid Outpatient Prescription Drug Policies: Findings From a National Survey, 2005 Update (Report). Washington, DC: The Kaiser Commission on Medicaid and the Uninsured; 2005.
3. Smith V, Gifford K, Ellis E, et al. Medicaid Budgets, Spending and Policy Initiatives in State Fiscal Years 2005 and 2006: Results From a 50-State Survey. Washington, DC: The Kaiser Commission on Medicaid and the Uninsured [Kaiser Family Foundation web site]. October 2005. Available at: http://www.kff.org/medicaid/upload/Medicaid-Budgets-Spending-and-Policy- Initiatives-in-State-Fiscal-Years-2005-and-2006-report.pdf. Accessed May 30, 2007.
4. Simon K, Tennyson S, Hudman J. What Policies are States Using to Control Medicaid Prescription Drug Spending During 1990-2004, and How Effective are They? Ithaca NY: Cornell University; 2006.
5. Fischer MA, Choudhry NK, Winkelmayer WC. Impact of Medicaid prior authorization on angiotensin-receptor blockers: can policy promote rational prescribing? Health Aff. 2007;26:800-807.
6. Moore WJ, Newman RJ. Drug formulary restrictions as a cost-containment policy in Medicaid programs. J Law Econ. 1993;36:71-97.
7. Smalley WE, Griffin MR, Fought RL, et al. Effect of a prior-authorization requirement on the use of nonsteroidal antiinflammatory drugs by Medicaid patients. N Engl J Med. 1995;15:1612-1617.
8. Schneeweiss S, Maclure M, Carleton B, et al. Clinical and economic consequences of a reimbursement restriction of nebulised respiratory therapy in adults: direct comparison of randomised and observational evaluations. BMJ. 2004;328:560-567.
9. Fischer MA, Schneeweiss S, Avorn J, et al. Medicaid prior-authorization programs and the use of cyclooxygenase-2 inhibitors. N Engl J Med. 2004;351:2187-2194.
10. Murawski M, Abdelgawad T. Exploration of the impact of preferred drug lists on hospital and physician visits and the costs to Medicaid. Am J Manag Care. 2005;11:SP35-SP42.
11. Cunningham PJ. Medicaid cost containment and access to prescription drugs. Health Aff. 2005;24:780-789.
12. MacKinnon NJ, Kumar R. Prior authorization programs: a critical review of the literature. J Manag Care Pharm. 2001;4:297-302.
13. Soumerai SB. Benefits and risks of increasing restrictions on access to costly drugs in Medicaid. Health Aff. 2004;23:135-146.
14. Stuart B, Zacker C. Who bears the burden of Medicaid drug copayment polices? Health Aff. 1999;18:201-212.
15. Soumerai SB, McLaughlin TJ, Ross-Degnan D, et al. Effects of limiting Medicaid drug-reimbursement benefits on the use of psychotropic agents and acute mental health services by patients with schizophrenia. N Engl J Med. 1994;331:650-655.
16. Tamblyn R, Laprise R, Hanley J, et al. Adverse events associated with prescription drug cost-sharing among poor and elderly persons. JAMA. 2001;285:421-429.
17. Owens MK. State Medicaid program issues: preferred drug lists. National Pharmaceutical Council. 2004. Available at: http://www.npcnow.org/resources/ PDFs/PDLbrief.pdf. Accessed May 30, 2007.
18. Kaiser Commission on Medicaid, and the Uninsured. Prior authorization for Medicaid prescription drugs in five states: lessons for policy makers [Kaiser Family Foundation web site]. April 2003. Available at: http://www.kff.org/ medicaid/loader.cfm?url=/commonspot/security/getfile.cfm&PageID=14324. Accessed May 30, 2007.
19. Ketcham JD, Epstein AJ. Which physicians are affected most by Medicaid preferred drug lists for statins and antihypertensives? Pharmacoeconomics. 2007;24(Suppl 3):27-40.
20. Wang YR, Pauly MV, Lin YA. Impact of Maine's Medicaid drug formulary change on non-Medicaid markets: spillover effects of a restrictive drug formulary. Am J Manag Care. 2003;9:686-696.
21. Wang YR, Pauly MV. Spillover effects of restrictive drug formularies on physician prescribing behavior: evidence from Medicaid. J Econ Manag Strat. 2005;14:755-773.
22. Hamel MB, Epstein AM. Prior-authorization programs for controlling drug spending. N Engl J Med. 2004;3 51:2156 -2158.
23. Woolhandler S, Campbell T, Himmelstein DU. Costs of health care administration in the United States and Canada. N Engl J Med. 2003;349:768-775.
24. Kahn JG, Kronick R, Kreger M, et al. The cost of health insurance administration in California: estimates for insurers, physicians and hospitals. Health Aff. 2005;24:1629-1639.
25. Bukstein DA, Cherayil GA, Gepner AD, et al. The economic burden associated with prior authorizations in an allergist office. Allergy Asthma Proc. 2006;27:119-122.
26. Borger C, Smith S, Truffer C, et al. Health spending projections through 20.15: changes on the horizon [Health Aff. web site]. February 22, 2006. Available at: http://content.healthaffairs.org/cgi/reprint/hlthaff.25.w61v1.pdf. Accessed May 30, 2007.
27. Holahan J, Ghosh A. Dual eligibles: Medicaid enrollment and spending for Medicare beneficiaries 2003 [Kaiser Commission on Medicaid and the Uninsured web site]. July 2005. Available at: http://www.kff.org/medicaid/upload/ 7346%20Dual%20Eligibles_Enrollment%20and%20Spending_ Beneficiaries_Final_revised%207_28.pdf. Accessed May 30, 2007.
28. Department of Health and Human Services, Centers for Medicare and Medicaid Services. Medicare program: Medicare prescription drug benefit. Fed Regist. 2005;70:4351. Available at: http://a257.g.akamaitech.net/7/257/2422/ 01jan20051800/edocket.access.gpo.gov/2005/pdf/051321.pdf. Accessed May 30, 2007.
29. Hoadley JE, Hargrave E, Cubanski J, et al. An in-depth examination of formularies and other features of Medicare drug plans [Kaiser Family Foundation web site]. April 2006. Available at: http://www.kff.org/medicare/upload/7489. pdf. Accessed May 30, 2007.
30. National Pharmaceutical Council. Pharmaceutical Benefits Under State Medical Assistance Programs. Reston, VA: National Pharmaceutical Council; 2004.
31. Virabhak S, Shinogle JA. Physicians' prescribing responses to a restricted, formulary: the impact of Medicaid preferred drug lists in Illinois and Louisiana. Am J Manag Care. 2005;11:SP14-SP20.
32. Lichtenberg FR. The effects of access restrictions on the vintage of drugs used by Medicaid, enrollees. Am J Manag Care. 2005;11:SP7-SP13.
33. Centers for Medicare and Medicaid Services. Estimated prescriptions filled for Medicare beneficiaries with drug coverage through 5-31-06 [Centers for Medicare and. Medicaid Services web site]. July 17, 2006. Available at: http://www.cms.hhs.gov/PrescriptionDrugCovGenIn/Downloads/ PartDPrescriptionClaimsData.zip. Accessed May 30, 2007.
34. Chernick MR. Bootstrap Methods: A Practitioner's Guide. New York, NY: John Wiley and Sons; 1999:150-151.
35. Särndal CE, Swensson B, Wretman J. Model Assisted Survey Sampling. New York: Springer-Verlag; 1992.
36. United States Department of Labor, Bureau of Labor Statistics, Occupational Employment Statistics [online database]. May 2005. Available at: http://data.bls.gov/oes/search.do. Accessed February 23, 2007.
37. Kirking DM, Lee .JA, Ellis JJ, et al. Patient-reported under use of prescription medications: a comparison of nine surveys. Med Care Res Rev. 2006;63:427-446.
38. Congressional Budget Office. Fact sheet for CBO's March 2006 base-line: Medicare. [Congressional Budget Office website]. March 15, 2006. Available at: www.cbo.gov/budget/factsheets/2006b/medicare.pdf. Accessed May 30, 2007.
39. Sloan F, Mitchell J, Cromwell J. Physician participation in state Medicaid programs. J Hum Resour. 1978;13(Suppl):211-245.
40. Holtz-Eakin D. Letter to the Honorable Joe Barton: updated estimates of spending for the Medicare prescription drug program [Congressional Budget Office web site]. March 4, 2005. Available at: http://cbo.gov/showdoc.cfm?index= 6139&sequence=0 Accessed May 30, 2007.
41. Danzon PM. Hidden overhead costs: is Canada's system really less expensive? Health Aff. 1992;11:21-43.